x
Filter:
Filters applied
- Regular Research Articles
- cardiovascular diseaseRemove cardiovascular disease filter
- FCRemove FC filter
- Journal of Lipid ResearchRemove Journal of Lipid Research filter
Publication Date
Please choose a date range between 2020 and 2021.
Regular Research Articles
2 Results
- Research ArticleOpen Access
Carboxylesterase 1d (Ces1d) does not contribute to cholesteryl ester hydrolysis in the liver
Journal of Lipid ResearchVol. 62100093Published online: June 17, 2021- Jihong Lian
- Jelske N. van der Veen
- Russell Watts
- René L. Jacobs
- Richard Lehner
Cited in Scopus: 0The liver is the central organ regulating cholesterol synthesis, storage, transport, and elimination. Mouse carboxylesterase 1d (Ces1d) and its human ortholog CES1 have been described to possess lipase activity and play roles in hepatic triacylglycerol metabolism and VLDL assembly. It has been proposed that Ces1d/CES1 might also catalyze cholesteryl ester (CE) hydrolysis in the liver and thus be responsible for the hydrolysis of HDL-derived CE; this could contribute to the final step in the reverse cholesterol transport (RCT) pathway, wherein cholesterol is secreted from the liver into bile and feces, either directly or after conversion to water-soluble bile salts. - Research ArticleOpen Access
Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux
Journal of Lipid ResearchVol. 62100004Published online: November 23, 2020- Oktawia Nilsson
- Mikaela Lindvall
- Laura Obici
- Simon Ekström
- Jens O. Lagerstedt
- Rita Del Giudice
Cited in Scopus: 0Apolipoprotein A-I (ApoA-I) of high density lipoproteins (HDLs) is essential for the transportation of cholesterol between peripheral tissues and the liver. However, specific mutations in ApoA-I of HDLs are responsible for a late-onset systemic amyloidosis, the pathological accumulation of protein fibrils in tissues and organs. Carriers of these mutations do not exhibit increased cardiovascular disease risk despite displaying reduced levels of ApoA-I/HDL cholesterol. To explain this paradox, we show that the HDL particle profiles of patients carrying either L75P or L174S ApoA-I amyloidogenic variants show a higher relative abundance of the 8.4-nm versus 9.6-nm particles and that serum from patients, as well as reconstituted 8.4- and 9.6-nm HDL particles (rHDL), possess increased capacity to catalyze cholesterol efflux from macrophages.